tildrakizumab-asmn

FDA Drug Profile — ILUMYA

Drug Details

Generic Name
tildrakizumab-asmn
Brand Names
ILUMYA
Application Number
BLA761067
Sponsor
Sun Pharmaceutical Industries, Inc.
NDC Codes
1
Dosage Forms
INJECTION, SOLUTION
Routes
SUBCUTANEOUS
Active Ingredients
TILDRAKIZUMAB

Indications and Usage

1 INDICATIONS AND USAGE ILUMYA ® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ILUMYA is an interleukin-23 antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ( 1 )